EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Dual targeting of BCR::ABL1 and DNA methylation in advanced CML: A 3-year survival analysis of TKI-Azacitidine combination therapy

Zhuming Yang iD, Danlei Han, Renying Ge, Zhenhao Wang, Hanlin Du, Yigang Guo, Zhe Zhao, Li Liu, Jun Qin, Bangwei Yu, Jie Hu, Xiya Gui und 8 weitere

Therapeutic Advances in Hematology · 2026-07 · 17

DOI: 10.1177/20406207261474931 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Hematology, online erschienen am 17.08.2026. Verfasst von Zhuming Yang und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Advanced-phase chronic myeloid leukemia (CML) remains associated with poor outcomes despite advances in tyrosine kinase inhibitor (TKI) therapy, underscoring the need for more effective treatment approaches.

Objectives

This multicenter study evaluated the efficacy and safety of tyrosine kinase inhibitor (TKI) plus azacitidine (with optional low-dose chemotherapy) in advanced-phase CML.

Design

Prospective multicenter single-arm study.

Methods

41 patients with accelerated- (AP) or blast-phase (BP) CML received azacitidine 75 mg/m 2 /day for 7 days per 28-day cycle (6 cycles) plus TKIs selected by ABL1 mutation status; chemotherapy was added based on early response. Major hematologic response (MaHR) was the primary endpoint. The secondary endpoints included cytogenetic/molecular responses—major cytogenetic response (MCyR), major molecular response (MMR), and undetectable minimal disease (UMD) — along with progression-free survival (PFS) and overall survival (OS). Adverse events (AEs) were documented.

Results

Among 36 evaluable patients (median age 51 years; range: 24-77; AP: 13, BP: 23) after excluding 5 noncompliant patients, 63.9% achieved MaHR, with a median response time of 1.33 months. The cumulative 3-year response rates were as follows: MCyR, 48.5%; MR2.0 (BCR::ABL1 IS ≤1%), 16.3%; MMR, 21.8%; and UMD, 14.2%. Patients maintained sustainable responses during follow-up. Four hematopoietic stem cell transplantation (HSCT) recipients maintained durable remission with TKI consolidation. At 28.1-month median follow-up, median OS was not reached and median PFS was 8.17 months; estimated 3-year OS and PFS rates were 50.3% and 41.1%, respectively. Elevated baseline WBC count and BCR::ABL1 transcript levels predicted poor survival. Hematologic toxicities of grade 3 or higher occurred in 55.6% of patients, including neutropenia (36.1%), thrombocytopenia (33.3%).

Conclusion

TKI–azacitidine therapy demonstrated promising efficacy and acceptable tolerability in patients with advanced-phase CML and may represent a feasible treatment option for this high-risk population.

Schlagwörter

Stichwörter der Autor:innen

DNA methylationazacitidinechronic myeloid leukemiacombination therapytyrosine kinase inhibitors

Autor:innen und Institutionen

  • Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Department of Hematology, Yichang Central Hospital, Yichang, Hubei, China.
  • Department of Hematology, Xianning Central Hospital, Xianning, China.
  • Department of Hematology, Hubei University of Medicine, Taihe Hospital, Shiyan, Hubei, China.
  • Department of Hematology, Minda Hospital of Hubei University for Nationalities, Enshi, Hubei, China.
  • Department of Hematology, Shiyan Renmin Hospital of Hubei Medical University, Shiyan, China.

ORCID-Profile: Zhuming Yang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Yang, Z., Han, D., Ge, R., Wang, Z., Du, H., Guo, Y., Zhao, Z., Liu, L., Qin, J., Yu, B., Hu, J., Gui, X., Su, M., Chen, S., Jiang, D., Zheng, J., Wang, H., Meng, L., Li, W., & Hong, Z. (2026). Dual targeting of BCR::ABL1 and DNA methylation in advanced CML: A 3-year survival analysis of TKI-Azacitidine combination therapy. Therapeutic Advances in Hematology, 17. https://doi.org/10.1177/20406207261474931

Vancouver

Yang Z, Han D, Ge R, Wang Z, Du H, Guo Y, et al. Dual targeting of BCR::ABL1 and DNA methylation in advanced CML: A 3-year survival analysis of TKI-Azacitidine combination therapy. Therapeutic Advances in Hematology. 2026;17. doi:10.1177/20406207261474931

BibTeX
@article{Yang2026,
  author = {Yang, Zhuming and Han, Danlei and Ge, Renying and Wang, Zhenhao and Du, Hanlin and Guo, Yigang and Zhao, Zhe and Liu, Li and Qin, Jun and Yu, Bangwei and Hu, Jie and Gui, Xiya and Su, Meifang and Chen, Shiming and Jiang, Daozi and Zheng, Jing and Wang, Hongxiang and Meng, Li and Li, Weiming and Hong, Zhenya},
  title = {Dual targeting of BCR::ABL1 and DNA methylation in advanced CML: A 3-year survival analysis of TKI-Azacitidine combination therapy},
  journal = {Therapeutic Advances in Hematology},
  year = {2026},
  volume = {17},
  doi = {10.1177/20406207261474931}
}
Kostenlos starten →